According to Zacks, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. “
Other equities analysts also recently issued reports about the company. Barclays assumed coverage on Revance Therapeutics in a research report on Tuesday, June 11th. They set an overweight rating and a $28.00 price objective for the company. ValuEngine upgraded Revance Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Mizuho reiterated a buy rating and set a $37.00 price objective on shares of Revance Therapeutics in a research report on Wednesday, April 24th. William Blair reiterated an outperform rating on shares of Revance Therapeutics in a research report on Tuesday, August 6th. Finally, BidaskClub upgraded Revance Therapeutics from a sell rating to a hold rating in a research report on Wednesday, July 31st. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $33.09.
Shares of NASDAQ RVNC opened at $11.98 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.13 and a current ratio of 5.59. The business’s 50 day simple moving average is $12.44. The firm has a market capitalization of $551.25 million, a P/E ratio of -3.04 and a beta of 1.00. Revance Therapeutics has a 12-month low of $10.37 and a 12-month high of $27.80.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.86). Revance Therapeutics had a negative return on equity of 79.28% and a negative net margin of 3,745.97%. As a group, equities research analysts forecast that Revance Therapeutics will post -3.68 earnings per share for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its position in Revance Therapeutics by 2.4% in the first quarter. JPMorgan Chase & Co. now owns 3,897,870 shares of the biopharmaceutical company’s stock worth $61,431,000 after purchasing an additional 92,811 shares during the period. Renaissance Technologies LLC lifted its position in Revance Therapeutics by 47.5% in the second quarter. Renaissance Technologies LLC now owns 1,330,973 shares of the biopharmaceutical company’s stock worth $17,263,000 after purchasing an additional 428,900 shares during the period. Rice Hall James & Associates LLC lifted its position in Revance Therapeutics by 654.1% in the second quarter. Rice Hall James & Associates LLC now owns 882,769 shares of the biopharmaceutical company’s stock worth $11,450,000 after purchasing an additional 765,701 shares during the period. Geode Capital Management LLC lifted its position in Revance Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 385,818 shares of the biopharmaceutical company’s stock worth $7,766,000 after purchasing an additional 48,325 shares during the period. Finally, Deutsche Bank AG lifted its position in Revance Therapeutics by 51.1% in the fourth quarter. Deutsche Bank AG now owns 331,820 shares of the biopharmaceutical company’s stock worth $6,678,000 after purchasing an additional 112,193 shares during the period. Hedge funds and other institutional investors own 94.81% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Recommended Story: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.